322 related articles for article (PubMed ID: 22388936)
1. Mutation of the parkinsonism gene ATP13A2 causes neuronal ceroid-lipofuscinosis.
Bras J; Verloes A; Schneider SA; Mole SE; Guerreiro RJ
Hum Mol Genet; 2012 Jun; 21(12):2646-50. PubMed ID: 22388936
[TBL] [Abstract][Full Text] [Related]
2. Hereditary Parkinsonism-Associated Genetic Variations in PARK9 Locus Lead to Functional Impairment of ATPase Type 13A2.
Park JS; Sue CM
Curr Protein Pept Sci; 2017; 18(7):725-732. PubMed ID: 26965689
[TBL] [Abstract][Full Text] [Related]
3. Atp13a2-deficient mice exhibit neuronal ceroid lipofuscinosis, limited α-synuclein accumulation and age-dependent sensorimotor deficits.
Schultheis PJ; Fleming SM; Clippinger AK; Lewis J; Tsunemi T; Giasson B; Dickson DW; Mazzulli JR; Bardgett ME; Haik KL; Ekhator O; Chava AK; Howard J; Gannon M; Hoffman E; Chen Y; Prasad V; Linn SC; Tamargo RJ; Westbroek W; Sidransky E; Krainc D; Shull GE
Hum Mol Genet; 2013 May; 22(10):2067-82. PubMed ID: 23393156
[TBL] [Abstract][Full Text] [Related]
4. A truncating mutation in ATP13A2 is responsible for adult-onset neuronal ceroid lipofuscinosis in Tibetan terriers.
Farias FH; Zeng R; Johnson GS; Wininger FA; Taylor JF; Schnabel RD; McKay SD; Sanders DN; Lohi H; Seppälä EH; Wade CM; Lindblad-Toh K; O'Brien DP; Katz ML
Neurobiol Dis; 2011 Jun; 42(3):468-74. PubMed ID: 21362476
[TBL] [Abstract][Full Text] [Related]
5. Mutations in the ATP13A2 gene and Parkinsonism: a preliminary review.
Yang X; Xu Y
Biomed Res Int; 2014; 2014():371256. PubMed ID: 25197640
[TBL] [Abstract][Full Text] [Related]
6. ATP13A2 missense variant in Australian Cattle Dogs with late onset neuronal ceroid lipofuscinosis.
Schmutz I; Jagannathan V; Bartenschlager F; Stein VM; Gruber AD; Leeb T; Katz ML
Mol Genet Metab; 2019 May; 127(1):95-106. PubMed ID: 30956123
[TBL] [Abstract][Full Text] [Related]
7. Mutations in ATP13A2 (PARK9) are associated with an amyotrophic lateral sclerosis-like phenotype, implicating this locus in further phenotypic expansion.
Spataro R; Kousi M; Farhan SMK; Willer JR; Ross JP; Dion PA; Rouleau GA; Daly MJ; Neale BM; La Bella V; Katsanis N
Hum Genomics; 2019 Apr; 13(1):19. PubMed ID: 30992063
[TBL] [Abstract][Full Text] [Related]
8. Lysosomal Storage of Subunit c of Mitochondrial ATP Synthase in Brain-Specific Atp13a2-Deficient Mice.
Sato S; Koike M; Funayama M; Ezaki J; Fukuda T; Ueno T; Uchiyama Y; Hattori N
Am J Pathol; 2016 Dec; 186(12):3074-3082. PubMed ID: 27770614
[TBL] [Abstract][Full Text] [Related]
9. Loss-of-function mutations in the ATP13A2/PARK9 gene cause complicated hereditary spastic paraplegia (SPG78).
Estrada-Cuzcano A; Martin S; Chamova T; Synofzik M; Timmann D; Holemans T; Andreeva A; Reichbauer J; De Rycke R; Chang DI; van Veen S; Samuel J; Schöls L; Pöppel T; Mollerup Sørensen D; Asselbergh B; Klein C; Zuchner S; Jordanova A; Vangheluwe P; Tournev I; Schüle R
Brain; 2017 Feb; 140(2):287-305. PubMed ID: 28137957
[TBL] [Abstract][Full Text] [Related]
10. A one base pair deletion in the canine ATP13A2 gene causes exon skipping and late-onset neuronal ceroid lipofuscinosis in the Tibetan terrier.
Wöhlke A; Philipp U; Bock P; Beineke A; Lichtner P; Meitinger T; Distl O
PLoS Genet; 2011 Oct; 7(10):e1002304. PubMed ID: 22022275
[TBL] [Abstract][Full Text] [Related]
11. The Parkinson-associated human P5B-ATPase ATP13A2 modifies lipid homeostasis.
Marcos AL; Corradi GR; Mazzitelli LR; Casali CI; Fernández Tome MDC; Adamo HP; de Tezanos Pinto F
Biochim Biophys Acta Biomembr; 2019 Oct; 1861(10):182993. PubMed ID: 31132336
[TBL] [Abstract][Full Text] [Related]
12. Clinical and ultrastructural findings in an ataxic variant of Kufor-Rakeb syndrome.
Pietrzak A; Badura-Stronka M; Kangas-Kontio T; Felczak P; Kozubski W; Latos-Bielenska A; Wierzba-Bobrowicz T; Florczak-Wyspianska J
Folia Neuropathol; 2019; 57(3):285-294. PubMed ID: 31588715
[TBL] [Abstract][Full Text] [Related]
13. Pathogenic effects of novel mutations in the P-type ATPase ATP13A2 (PARK9) causing Kufor-Rakeb syndrome, a form of early-onset parkinsonism.
Park JS; Mehta P; Cooper AA; Veivers D; Heimbach A; Stiller B; Kubisch C; Fung VS; Krainc D; Mackay-Sim A; Sue CM
Hum Mutat; 2011 Aug; 32(8):956-64. PubMed ID: 21542062
[TBL] [Abstract][Full Text] [Related]
14. Neuropathologic Findings in a Patient With Juvenile-Onset Levodopa-Responsive Parkinsonism Due to
Chien HF; Rodriguez RD; Bonifati V; Nitrini R; Pasqualucci CA; Gelpi E; Barbosa ER
Neurology; 2021 Oct; 97(16):763-766. PubMed ID: 34475127
[TBL] [Abstract][Full Text] [Related]
15. Partial loss of ATP13A2 causes selective gliosis independent of robust lipofuscinosis.
Rayaprolu S; Seven YB; Howard J; Duffy C; Altshuler M; Moloney C; Giasson BI; Lewis J
Mol Cell Neurosci; 2018 Oct; 92():17-26. PubMed ID: 29859891
[TBL] [Abstract][Full Text] [Related]
16. Altered apoptosis regulation in Kufor-Rakeb syndrome patients with mutations in the ATP13A2 gene.
Radi E; Formichi P; Di Maio G; Battisti C; Federico A
J Cell Mol Med; 2012 Aug; 16(8):1916-23. PubMed ID: 22117566
[TBL] [Abstract][Full Text] [Related]
17. From PARK9 to SPG78: The clinical spectrum of ATP13A2 mutations.
Erro R; Picillo M; Manara R; Pellecchia MT; Barone P
Parkinsonism Relat Disord; 2019 Aug; 65():272-273. PubMed ID: 31151786
[No Abstract] [Full Text] [Related]
18. ATP13A2 missense mutations in juvenile parkinsonism and young onset Parkinson disease.
Di Fonzo A; Chien HF; Socal M; Giraudo S; Tassorelli C; Iliceto G; Fabbrini G; Marconi R; Fincati E; Abbruzzese G; Marini P; Squitieri F; Horstink MW; Montagna P; Libera AD; Stocchi F; Goldwurm S; Ferreira JJ; Meco G; Martignoni E; Lopiano L; Jardim LB; Oostra BA; Barbosa ER; ; Bonifati V
Neurology; 2007 May; 68(19):1557-62. PubMed ID: 17485642
[TBL] [Abstract][Full Text] [Related]
19. A mixed breed dog with neuronal ceroid lipofuscinosis is homozygous for a CLN5 nonsense mutation previously identified in Border Collies and Australian Cattle Dogs.
Villani NA; Bullock G; Michaels JR; Yamato O; O'Brien DP; Mhlanga-Mutangadura T; Johnson GS; Katz ML
Mol Genet Metab; 2019 May; 127(1):107-115. PubMed ID: 31101435
[TBL] [Abstract][Full Text] [Related]
20. Novel ATP13A2 (PARK9) homozygous mutation in a family with marked phenotype variability.
Santoro L; Breedveld GJ; Manganelli F; Iodice R; Pisciotta C; Nolano M; Punzo F; Quarantelli M; Pappatà S; Di Fonzo A; Oostra BA; Bonifati V
Neurogenetics; 2011 Feb; 12(1):33-9. PubMed ID: 20853184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
